{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268807","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.768754+00:00","generated_at":"2026-06-09T00:25:28.885642+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Seres Q3 2023 VOWST sales $7.6M; cuts 41% workforce, targets $75-85M annual savings","bullets":["Q3 net loss $47.9M vs $60.0M YoY; VOWST net sales $7.6M from 506 units in first full quarter.","1,513 prescription enrollment forms received, 934 patient starts; 698 unique HCPs prescribed VOWST.","Workforce reduction of ~160 positions (41%) to generate $75-85M annual cash savings in 2024.","Restructuring focuses on VOWST launch and SER-155 Phase 1b study; cash $169.9M expected into Q4 2024.","Eligible for $45M Tranche B from Oaktree upon $35M trailing VOWST sales by Sep 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268807","json":"https://secwatch.observer/filing/0001193125-23-268807.json","markdown":"https://secwatch.observer/filing/0001193125-23-268807.md","text":"https://secwatch.observer/filing/0001193125-23-268807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523268807/0001193125-23-268807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523268807/d559654d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:25:28.885642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5839a79bfce320d277b615a6476484daa8ff2b34","claim":"Seres Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income net loss of $47.9 million.","evidence_excerpt":"Seres reported a net loss of $47.9 million for the third quarter of 2023, as compared with a net loss of $60.0 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523268807/0001193125-23-268807-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $47.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}